Share this:
|
Funding Opportunities by Agency
| |
Discovery Boost Grants (DBG) high-risk, high-reward exploratory cancer research. Awards are for up to 2 years with $135,000 a year for direct costs, plus 10% allowable indirect costs. Due: 06/01/25
Mission Boost Grants (MBG) Stage I Mission Boost: $135,000/year direct cost for two years, plus 10% indirect costs. Stage II Mission Boost: Applicants may propose up to 18 months and $545,000 for direct costs, plus 10% indirect costs. Due: 06/01/25
Research Scholar Grants Awards are for up to 4 years with up to $215,000/year for direct costs, plus 10% allowable indirect costs. Due: 06/01/25
Postdoctoral Fellowship $66,000 Yr 1, $68,000 Yr 2, $70,0000 Yr 3, and additional $4,000/year Fellowship allowance. Due: 06/01/25
| |
AHA Postdoctoral Fellowship AHA's stipend matches the published NIH stipend for postdoctoral fellows at the time the AHA begins to accept proposals (July 1, 2025), plus 12,200 per year health insurance and 3,000/year for project support. Award is for 1-2 years. Due: 09/04/2025
2026 Merit Award $200,000 annually for 5 years including 10% indirects. LOI will be due in July 2025; date TBA.
| |
The Colorectal Cancer Alliance (the Alliance) is pleased to announce a Request for Proposals (RFP) for preclinical, translational and clinical research with the potential for high impact on treatment and survivorship of colorectal cancer. There are no application deadlines.
Applications will be accepted on a rolling basis.
| |
The FY25 PRCRP funding opportunity announcements for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the announcements are released. The PRCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY25 funding opportunities.
Ovarian Cancer Research Program
Investigator-Initiated Research Award Maximum funding of $1,050,000 total costs (including direct and indirect cost). For the Partnering PI option: $1,400,000 total costs (including direct and indirect cost). Maximum period of performance is four years.
Pilot Award $350,000 total costs (including direct and indirect costs). Maximum period of performance is two years.
Peer Reviewed Cancer Research Program
Impact Award $1,000,000 directs for three years plus indirects. $1,250,000 directs plus indirects for the Partnering PI option. Maxium period of performance is thee years.
| |
2025 Path to a Cure (PTAC) – Pioneer Award with Letter of Intent (LOI) . Applicants may propose an amount necessary to complete the proposed research, plus an additional twelve percent (12%) of indirect costs. Up to three (3) years of funding may be requested. LOI: Rolling/closes on December 5, 2025. Full Application: As agreed upon/closes on December 5, 2025
| |
Damon Runyon Fellowship Award Stipend: $70,000 Yr 1, $72,000 Yr 2, $74,000, Yr 3, and $76,000 Yr 4 plus 2K/year expense allowance. The Damon Runyon Cancer Research Foundation will retire up to $100,000 of any qualifying medical school debt still owed by the awardee. Applications due by 08/15/25
Damon Runyon-St. Jude Pediatric Cancer Research Fellowship Award Stipend: $70,000 Yr 1, $72,000 Yr 2, $74,000, Yr 3, and $76,000, Yr 4 plus 2K/year expense allowance. The Damon Runyon will retire up to $100,000 of any qualifying medical school debt still owed by the Fellow. Applications due: 08/15/25
| |
NOT-OD-23-032 Notice of Special Interest (NOSI): Administrative Supplement for Continuity of Biomedical and Behavioral Research Among First-Time Recipients of NIH Research Project Grant Awards Up to 70K. Deadlines vary by awarding IC.
PAR-24-075 Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed) Application budgets are not limited but need to reflect the actual needs of the proposed project. Next due date:05/28/25 and 09/26/25
PAR-25-082 Co-infection and Cancer (R01 Clinical Trial Not Allowed) Application budgets are not limited but need to reflect the actual needs of the proposed project. New applications due: 06/05/25 and 10/05/25.
![]() PAR-23-145 Maximizing Investigators’ Research Award (MIRA) for Early Stage Investigators (ESI) (R35 - Clinical Trial Optional) up to $250,000 direct costs/year. Due: 08/03/25
PA-24-194 NIH Pathway to Independence Award (Parent K99/R00 – Independent Clinical Trial Not Allowed) Salary and research costs may be requested to the level provided by the awarding Institute or Center plus indirects. Next due dates: 06/12/25 and 10/12/25
PAR-25-083 Co-infection and Cancer (R21 Clinical Trial Not Allowed) The combined budget for direct costs for the two-year project period may not exceed $275,000 Next due dates: 06/16/25 and 10/16/25.
PAR-25-077 CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System (R01 Clinical Trial Not Allowed). 300K directs/year. Maximum project period is 3 years. LOI: due 30 days prior to application due date. Full application: 10/17/25.
| |
|
$300,000 for a three-year period. Letters of invitation and online nomination instructions will be sent to participating institutions beginning 06/01/205. Searle Scholars
| |
|
Vanderbilt-Ingram Cancer Center regularly solicits applications for pilot funding to support basic, translational, clinical or collaborative cancer research. Pilot funds allow investigators to collect preliminary data to support an application for independent research support through extramural, peer-reviewed funding. All pilot project awards are funded for one-year periods. For more information, contact us at viccresearchenterprise@vumc.org
| |
|
| NIH Standard Deadlines
June
R01 (New) Routing: 05/23/25, Sponsor: 06/05/25
U01 (New) Routing: 05/23/25, Sponsor: 06/05/25
K Series (New) Routing: 06/02/25, Sponsor: 06/12/25
R21 (New) Routing: 06/04/25, Sponsor: 06/16/25
July
R01 (Renewal, Resubmission, Revision) Routing: 06/25/25, Sponsor: 07/05/25
U01 (Renewal, Resubmission, Revision) Routing: 06/25/25, Sponsor: 07/05/25
K Series (New) Routing: 07/02/25, Sponsor: 07/12/25
R21 (New) Routing: 07/03/25, Sponsor: 07/16/25
August
F series (New, Renewal, Resubmission) Routing: 07/29/25, Sponsor: 08/08/25
R13, U13 (New, Renewal, Resubmission, Revision) Routing: 07/31/25, Sponsor: 08/12/25
September
P Series (New, Renewal, Resubmission, Revision) Routing: 09/15/25, Sponsor: 09/25/25
R18, U18, R25 (New, Renewal, Resubmission, Revision) Routing: 09/15/25, Sponsor: 09/25/25
T & D Series (New, Renewal, Resubmission, Revision) Routing 09/15/25, Sponsor: 09/25/25
C06/UC6
(New, Renewal, Resubmission, Revision) Routing: 09/15/25, Sponsor: 09/25/25
| |
|
| Missing PMCIDs and other common errors on proposals
The PMI grants team encourages applicants to review these items often overlooked for compliance on NIH proposals. View...
| |
|
Planning a proposal submission in the next 2 - 3 months? In an effort to better serve you, the PMI grants team requests that PIs and Fellows notify us as far in advance as possible of submission plans. This ensures ample time to complete departmental requirements and also route to OSP for review by their deadline. Here is the link to the new SRS intake tool for new/resubmission requests: REDCap
| |
|
Are you a Principal Investigator, Fellow, or Student looking for additional grant resources?
- Funding Opportunities
- Various Agency Submission Checklists
- Training
| |
We're here to help! Candice Stevens, Associate Director, Lauren Milam, Sr Financial Manager, Edith Ashcraft, Sr Financial Analyst, Cedric Duncan, Sr Financial Analyst, Doug Smith, Sr Financial Analyst, Leigh Thompson, Budget Accounting Analyst Post-Award, Karin Sack, Sr Grants Manager, and Alethea Kelly, Grants Manager.
| |
|
|
|
|
Vanderbilt University Medical Center 1161 21st Ave S | Nashville, TN 37232 US
|
|
